|
Patients treated: n = 7 | |
|
In-hospital follow-up | |
Clinical success (with improvement in at least one NYHA functional class after procedure) | 100% (7/7) |
NYHA functional class post procedure | |
Improvement by two NYHA functional classes | 29% (2/7) |
Improvement by one NYHA functional class | 71% (5/7) |
No improvement in NYHA functional class | 0% (0/7) |
NYHA functional class after procedure | |
NYHA class IV | 0% (0/7) |
NYHA class III | 29% (2/7) |
NYHA class II | 71% (5/7) |
NYHA class I | 0% (0/7) |
Residual mitral regurgitation after TMVI at hospital discharge | |
None | 29% (2/7) |
Trace or mild (MR grade I) | 57% (4/7) |
Moderate (MR grade 2) | 14% (1/7) |
Severe (MR grade 3) | 0% (0/7) |
Complications | |
Vascular access site bleeding complication | 0% (0/7) |
Device embolization | 0% (0/7) |
Need for second valve implantation | 0% (0/7) |
Cardiac perforation/cardiac tamponade | 0% (0/7) |
Major stroke | 0% (0/7) |
New arrhythmia | 14% (1/7) |
Conversion to open heart surgery | 0% (0/7) |
Acute kidney injury | 0% (0/7) |
LVOT obstruction by implanted mitral valve prosthesis | 0% (0/7) |
Major atrial septal defect (ASD) after TMVI, hemodynamically relevant | 43% (3/7) |
Interventional ASD closure | 29% (2/7) |
Pacemaker implantation post TMVI | 14% (1/7) |
In-hospital mortality rate | 14% (1/7) |
In-hospital stay from TMVI to hospital discharge (days, mean ± SD) | 12 ± 6.1 |
Clinical follow-up after hospital discharge | |
30-day mortality rate (all-cause) | 14% (1/7) |
6-month mortality rate (all-cause) | 14% (1/7) |
One-year mortality rate (all-cause, n = 6) | 17% (1/6) |
NYHA functional class at 30-day and 6-month follow-up (n = 6) | |
NYHA class IV | 0% (0/6) |
NYHA class III | 17% (1/6) |
NYHA class II | 83% (5/6) |
NYHA class I | 0% (0/6) |
NYHA functional class at 1-year follow-up (available in n = 5) | |
NYHA class IV | 0% (0/5) |
NYHA class III | 20% (1/5) |
NYHA class II | 80% (4/5) |
NYHA class I | 0% (0/5) |
|